# Enabling Oral Delivery of Peptides through Molecular and Formulation Design

Sumit Arora, PhD
Senior Principal Scientist
Pharmaceutical Product Development and Supply
J&J Innovative Medicine

CRS 2025 ANNUAL MEETING & EXPOSITION
PHILADELPHIA, PA
JULY 13-18, 2025
Johnson&Johnson Innovative Medicine
NEXT-GENERATION DELIVERY INNOVATIONS

# Challenges with Oral Delivery of Peptides

**Gastrointestinal (GI) tract**
A dynamic and harsh milieu

Variability of residence time, pH, Volume fluids, Enzymes, Fasted/Fed situation etc.




Stability?
Solubility?

Low Permeability/
Absorption ↓ due to
interaction with food

**Stomach**
- pH ~ 1-4
- Digestive enzymes

**Small intestines**
- pH ~ 5.5-7.5
- Digestive enzymes
- Bile

**Colon**
- pH ~ 5-7
- Microbiota
- Low water content



# Peptide oral delivery challenges require a collaborative approach



# Enabling Oral Delivery of Peptides through Molecular Design

Johnson&Johnson
Innovative Medicine

# Molecular Design – Making gut stable and permeable peptides




L-amino acids
unnatural AAs




D-amino
acids




azapeptide




Backbone
cyclization




α-methyl
α-substituted




β-methyl




Carbonyl
replacements




Peptidomimetics
– amide
isosteres




N-methyl




β-amino acids




Cyclization




Bicyclization



*J. Med. Chem.* **2022**, *65*, 6191-6206

# Molecular Design – Food Effect liabilities







Major physiological responses and changes in the luminal physicochemical characteristics after meal intake.

# Can we mitigate food effect of peptides by Molecular Design?

Summary of Food Effect of selected Compounds

| Species | Peptide A | Peptide B |
|---|---|---|
| Rat | ↓AUC >80% | Not tested |
| Dog | ↓AUC 80% | Not tested |
| Monkey | ↓AUC 45% | ↓AUC 94% |
| Human | ↓AUC 58% | ↓AUC 91% |

- Structurally similar peptides with different extent of negative food effect provided an opportunity to better understand negative food effect
- Point mutants of peptides were available to better understand which functional groups could influence the negative food effect to peptides

# Potential Causes of Food Effect For Peptides

✖ Stability of the peptide in the fed state – enzymes, increased pH

- Selected peptides were gut stable

✖ Dilution effect in fed state stomach

- Could be the cause; however, clinical data available which suggest otherwise

? Interaction with meal contents

- Could be the cause; however, clinical results cannot be explained

✔ Interaction with bile salts

- Hypothesis – Is interaction with bile the major contributor of observed food effect for selected peptides?

# Bile Mediated Interactions for selected Peptides




μFlux setup










μFlux was able to pick the ranking of bile mediated interactions for selected Peptides

# Flux of Point Mutants







- Little impact of bile concentration on flux for 3 out of 4 variants of Peptide C
- Flux of Peptide F is sensitive to fasted vs fed bile concetrations

# Enabling Oral Delivery of Peptides through Formulation Design

Johnson&Johnson
Innovative Medicine

# Technology Overview Enabling Oral Delivery of Peptides




*Chen et al. Theranostics* 2022; 12(3):1419-1439. doi:10.7150/thno.6174

novo nordisk®




Mycapssa® (octreotide) capsules 20mg

Rani THERAPEUTICS



# Oral Delivery of Peptides via Absorption Enhancer Technology

1. **Choose an AbE**
   - Effective & safe
   - Compatible with peptide

2. **Formulate IR or DR oral dosage form**
   - Release both peptide and AbE at a focal epithelial point*
   - Achieve the threshold concentration for the specific AbE
   - Avoid dilution and spreading




## Tips & Tricks




Maher & Brayden. Adv Drug Deliv Res 177, 113925 (2021)

# Absorption Enhancement of Synthetics – Size Matters!




Figure adapted from Enteris BioPharma website
https://enterisbiopharma.com/wp-content/uploads/2020/02/EBP_Corporate-Overview_February-2020.pdf

# Formulation Optimization – Co-release Drug and Peptide




- ↑ Lag time (FD4 and TPE), ↓ Oral BA of FD4 in rats
- Concomitant dosing (i.e. API-AbE co-release) → highest exposure
- Intestinal epithelium back to baseline permeability after a short duration of TPE exposure (60 min)



Salama, P. et al. *Pharmaceutical Compositions and Related Methods of Delivery* WO 2010032140, 2010

# Translation from *In vitro* to *In vivo*

*In Vitro* Caco-2 Cells → *Ex Vivo* GI Tissues → *In Situ* GI Perfusion, Instillation → *In Vivo* Oral BA in Pre-clinical Models → *In Vivo* Oral BA in Clinics




| Model | Enhance Ratio |
|---|---|
|  | 1.1-3.6, 63* |
|  | 1.7 |
|  | 1.4-3.8 |

*Glycyrrhzin + 200mM NaC10

| API | NaC10 (mg) | Oral BA (F%) |
|---|---|---|
| Zoledronic acid | 550 | 5% |
| Antisense Oligonucleotide (ISIS 104838) | 330-660 | 9.5% |
| Basal insulin (I338) | 550 | 1.5-2% |

- **Poor translatability** from *in vitro* or pre-clinical models to humans
- Non-rodent species (dogs, monkeys, minipigs) used for developing AbE formulations
- Enhan. Ratio in humans often unavailable (very low oral BA of non-AbE formulations)

# J&J Peptide AbE Formulation Development



# AbE Selection and Dose Evaluation in Rats

**Liquid Formulations**
- ✓ Identified from >250 in literature
- ✓ Solution/suspension in pH 7.4 PBS

**AbE Selection**
- ✓ ID/IC admin for PK endpoints
- ✓ 10 mg/kg API + 100 mg/kg AbE (60 mg/kg Peptel.)

**NaC10 Dose**
- ✓ IC admin for PK endpoints
- ✓ 10 mg/kg AP + 0-200 mg/kg NaC10

Sodium Caprate (**NaC10**)



**SNAC**



Sucrose Laurate (**SucC12**)



**Labrasol** ALF ™
- PEG-8 (MW 400) mono-/di-caprylate (C8)/caprate (C10)
- Mono-/di-/triglycerides

**Peptelligence ™**
- Citric acid
- Acrylcarnitine

ID or IC Instillation



- Male Sprague-Dawley rats
- n=3 each group
- PK at 2, 4, 6, 8, and 24 hr
- Fasted study










- NaC10 > Labrasol ~ Peptel. > SNAC ~ SucC12
- Peptide/NaC10 shows 19x (ID) and 124x (IC) AUC↑ in rats
- No further improvement above 50 mg/kg NaC10

# Co-Formulation of J&J Peptide and NaC10 in Tablets

**Oral Solid Formulations**
- ✓ High dose API + NaC10
- ✓ DR Tabs

**GI Site-Specific Release**
- ✓ Target various GI sites
- ✓ Fast release (high conc.)

**Peptide-AbE Co-Release**
- ✓ Concomitant release
- ✓ In intestines (DR Tab)

Site of Release for AbE Formulations

**Duodenum/jejunum**
High dose DR Tab + NaC10
(subcoat + pH 5.5 enteric coat)

**Ileocolon**
High dose DR Tab + NaC10
(subcoat + pH 7 enteric coat)








# Oral AbE Solid Formulation in Dogs

**Study 1: Oral BA of AbE Formulations**

- ✓ High dose J&J peptide in DR AbE Tabs vs. oral solution (non-AbE)
- ✓ Oral admin (fasted) to n = 3 male dogs for each formulation
- ✓ Parallel study design

**Study 2: Food Effect of DR (AbE) Tab**

- ✓ Low dose J&J peptide in DR Tab (pH 5.5) AbE
- ✓ Oral admin to n = 12 male dogs under fasted/fed conditions
- ✓ Cross-over study design

**Fasted**

10 min pre-dose

**pH 1.4** 0.1N HCl/KCl buffer

T0 = Dosing

+ 10 mL water

Fasted up to 4 h post-dose before food is given




- DR (pH 5.5) > DR (pH 7) > Oral solution (non-AbE)
- DR pH 5.5 has ~14x AUC↑, whereas only ~4x AUC↑ for DR pH 7 in comparison to the reference
- Target site of release in upper small intestine

**Fed**

20 min pre-dose

Gavage liquid meal

T0 = Dosing

+ 10 mL water

Fasted for the remaining day




- Dosing DR Tab with food shows limited effect on oral BA (minor ↓ in Cmax/AUC)
- DR Tab with food shows Tlag (no absorption) 0-4 hr, and Tmax↑ from 3.3 hr (fasted) to 6.0 hr (fed)

# Clinical Data of J&J Peptide AbE Formulations




| Treatment (n=10 healthy volunteers) | Cmax (ng/mL) | Tmax (h) | $AUCi_{inf}$ (ng.h/mL) | Rel BA (%) |
|---|---|---|---|---|
| Low dose Oral Solution, Fasted | 0.359 | 2 (1, 8) | 4.75 | 100 |
| Low dose DR Tab + NaC10, Fasted | 6.451 | 4 (1, 6) | 34.12 | 688.4 |
| Low dose DR Tab + NaC10, Fed | 1.770 | 12 (5, 24) | 34.44 | 435.1 |

- J&J Peptide DR Tab AbE shows ~7x AUC↑ than oral solution under fasted conditions

# PBBM of Oral JNJ Peptide AbE Formulations




*In vitro dissolution*




*Establishing Relationship Between AbE conc. with fold enhancement in permeation of drug*




Parameterization of Absorption PBPK Model




*Simulating release of C10 in gut lumen and calculating increase in permeation when conc. exceeds certain threshold*

Simulating the exposure of JNJ Peptide considering permeation enhancement by C10



# Lessons Learned from J&J Peptide Oral Product Dev

- Oral delivery of peptides requires a multi-faceted approach



- Combination of approaches through molecular and formulation design could enable successful PoC

- AbE formulation development relies on appropriate design of pre-clinical studies and careful data interpretation

- Novel *in silico* models can help to better guide future formulation development and optimization

# Acknowledgments

**Pharmaceutical Product Development and Supply**

Dajun Sun, PhD
Cecília Michalowski, PhD
Geraldine Broeckx, PhD
Jan Bevernage, PhD
Gopal Ranjan, PhD
Riet Dams, PhD

**Analytical Development**

Nathan Schulpen, PhD
Melissa Cleymans, PhD
Shauni Geeraerts, PhD
Ellen Verheyen, PhD

**Preclinical Sciences and Translational Safety**

Beverly Knight, PhD
Anthony Ndifor, PhD
Darren Moss, PhD

**Clinical Pharmacology – Global Development**

Tristan Bauget, PhD
Teddy Kosoglou, PhD